Ovarian function following intra-ovarian injection of platelet rich plasma in premature ovarian aging

Shakeela Ishrat, Jesmine Banu, Farzana Deeba, Sharmin Salam, Chandana Saha, Arifa Akhtar


Background: Premature ovarian aging as evidenced by AMH levels less than 0.5 ng/ml is predictive of reduced success in management of infertility. The most effective treatment is in vitro fertilization which is not affordable or acceptable to most of our patients with low socioeconomic background. Intra-ovarian injection of autologous platelet rich plasma (PRP) improves the ovarian reserve markers but it remains to be seen whether it improves the pregnancy rate.

Methods: This was a prospective study of 29 patients with poor ovarian reserve (age between 30-40 years, AMH<0.5 ng/ml), AFC<4 in both ovaries) who received intra ovarian injection of platelet rich plasma. The patients were followed up for one year and data was collected about clinically relevant outcomes like pregnancy.

Results: Four women (13.8%) had pregnancy, of which 3 were spontaneous and one was following ovarian stimulation and intrauterine insemination. All had diagnosed clinical pregnancy, of which two women had live birth.

Conclusions: Given the 13.8% rate of pregnancy within one year we can speculate that PRP injection may be a reasonable alternative to in vitro fertilization in women with diminished ovarian reserve.



Diminished ovarian reserve, Platelet rich plasma, In vitro fertilization

Full Text:



Barad DH, Albertini DF, Gleicher N. Endocrine effects of intra ovarian injection of platelet rich plasma in women with premature ovarian aging. Fertil Steril. 2020;e89:210-6.

Park H, Ulin M, Cetin E. Ovarian Rejuvination using platelet rich plasma: a promising option for women in early menopause to have a baby. Reproductive Sciences. 2020;12:21-4.

Urman B, Boza A, Balaban B. Platelet rich plasma another add-on treatment getting out of hand? How can clinicians preserve the best interest of their patients? Hum Reprod. 2019;34(11):2099-103.

Sills SC, Wood HS. Autologous activated platelet rich plasma injection into adult human ovary tissue: molecular mechanism, analysis and discussion of reproductive response. Bioscience Reports. 2019;BSR20190805.

Vo TKC, Tanaka Y, Kawamura K. Ovarian rejuvenation using autologous platelet rich plasma. Endocrine. 2021;1:15-27.

Dawood AS, Salem HA. Current clinical applications of platelet rich plasma in various gynecological disorders: An appraisal of theory and practice.Club Exp Reprod Med. 2018;45(2):67-74.

Pantos K, Simopoulou M, Pantou A, Rapani A, Tsioulou P, Nitsos N, et al. A Case Series on Natural Conceptions Resulting in Ongoing Pregnancies in Menopausal and Prematurely Menopausal Women Following Platelet-Rich Plasma Treatment. Cell Transplantation. 2019;28(9-10):1333-40.

Uddin MJ, Banu J, Ishrat S, Sultana S, Munira S, Shume MM, et al. Effect of autologous platetel rich plasma on anti mullerian hormonr and antral follicle count in subfertile women with poor ovarian reserve. Int J reprod Contracept Obstet Gynecol. 2022;1(2):292-8.

La Marca A, Nelson SM, Siginolfi G, Manno M, Baraldi E, Roli L, et al. Anti-mullerian hormone based prediction model for a live birth in assisted reproduction. Reprod BioMed Online. 2011;22(4):341-49.

Brodin T, Hadziosmanovic N, Burglund L, Olovsson M, Holte J. Antimullerian hormone levels are strongly associated with live birth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98(3):1107-14.

Elnashar AB. Intra ovarian platelet rich plasma: current status. Middle East Fertility Society Journal 2020;1021;26:30.

Melo P, Navarro C, Jones C, Coward K, Coleman L. The use of autologous platelet rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. J Assist Reprod Genetics. 2020;37:855-63.

Petryk N, Petryk M. Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)—a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment. Reproductive Sciences. 2020;27:1975-82.

Sfakianoudis K, Simopoulou M, Grigoriodis S, Pontou A, Tsiolou P, Maziotis E, et al. Reactivating ovarian function through autologous platelet rich plasma intra ovarian infusion: pilot data on premature ovarian insufficiency, premenopausal,menopausal and poor responder women. J Club med. 2020;9:1809.

Cakiroglu Y, Saltik A, Yuceturk A, Karaosmanoglu O, Kopuk SY, Scott RT, et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and ivf outcome parameters in women with primary ovarian insufficiency. Aging. 2020;12(11):11211.

Farimani M, Nazari M, Mohammadi S, Aliabad RA. Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria. Reproductive Biology and Endocrinology. 2021;19:137.

Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. Reprod Biomed Online. 2019;39(3):467.

Practice Committee of American Society of Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151-6.

Overveek A, Broekmans FJ, Hehenkamp WJ. Intracycle fluctuations of anti-Mullerian hormone in normal women with a regular cycle: a re- analysis. Reprod Biomed Online. 2012.